Special Considerations for Prophylaxis for and Treatment of Anthrax in Pregnant and Postpartum Women

• Main Authors: Dana Meaney-Delman, Marianne E. Zotti, Andreea A. Creanga, Lara K. Misegades, Etobssie Wako, Tracee A. Treadwell, Nancy E. Messonnier, Denise J. Jamieson
• Format: Article
• Language: English
• Published: Centers for Disease Control and Prevention 2014-02-01
• Series: Emerging Infectious Diseases
• Subjects: Bacillus anthracis; anthrax; antibacterial agents; antimicrobial drugs; pregnancy; postpartum period
• Online Access: https://wwwnc.cdc.gov/eid/article/20/2/13-0611_article

In August 2012, the Centers for Disease Control and Prevention, in partnership with the Association of Maternal and Child Health Programs, convened a meeting of national subject matter experts to review key clinical elements of anthrax prevention and treatment for pregnant, postpartum, and lactating (P/PP/L) women. National experts in infectious disease, obstetrics, maternal fetal medicine, neonatology, pediatrics, and pharmacy attended the meeting, as did representatives from professional organizations and national, federal, state, and local agencies. The meeting addressed general principles of prevention and treatment for P/PP/L women, vaccines, antimicrobial prophylaxis and treatment, clinical considerations and critical care issues, antitoxin, delivery concerns, infection control measures, and communication. The purpose of this meeting summary is to provide updated clinical information to health care providers and public health professionals caring for P/PP/L women in the setting of a bioterrorist event involving anthrax.